Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

DOI Web Site Web Site 被引用文献75件 参考文献76件
  • V. Gopalakrishnan
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • C. N. Spencer
    Department of Epidemiology, Human Genetics and Environmental Sciences, University of Texas School of Public Health, Houston, TX 77030, USA.
  • L. Nezi
    Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • A. Reuben
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • M. C. Andrews
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • T. V. Karpinets
    Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • P. A. Prieto
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • D. Vicente
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • K. Hoffman
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • S. C. Wei
    Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • A. P. Cogdill
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • L. Zhao
    Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • C. W. Hudgens
    Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • D. S. Hutchinson
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
  • T. Manzo
    Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • M. Petaccia de Macedo
    Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • T. Cotechini
    Department of Cell, Developmental and Cell Biology, Oregon Health and Sciences University, Portland, OR 97239, USA.
  • T. Kumar
    Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • W. S. Chen
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • S. M. Reddy
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • R. Szczepaniak Sloane
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • J. Galloway-Pena
    Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • H. Jiang
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • P. L. Chen
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • E. J. Shpall
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • K. Rezvani
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • A. M. Alousi
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • R. F. Chemaly
    Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • S. Shelburne
    Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • L. M. Vence
    Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • P. C. Okhuysen
    Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • V. B. Jensen
    Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • A. G. Swennes
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
  • F. McAllister
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • E. Marcelo Riquelme Sanchez
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Y. Zhang
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • E. Le Chatelier
    Centre de Recherche de Jouy-en-Josas, Institut National de la Recherche Agronomique, 78352 Jouy-en-Josas, France.
  • L. Zitvogel
    Centre d’Investigation Clinique Biothérapie, Institut Gustave-Roussy, 94805 Villejuif Cedex, France.
  • N. Pons
    Centre de Recherche de Jouy-en-Josas, Institut National de la Recherche Agronomique, 78352 Jouy-en-Josas, France.
  • J. L. Austin-Breneman
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • L. E. Haydu
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • E. M. Burton
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • J. M. Gardner
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • E. Sirmans
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • J. Hu
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • A. J. Lazar
    Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • T. Tsujikawa
    Department of Cell, Developmental and Cell Biology, Oregon Health and Sciences University, Portland, OR 97239, USA.
  • A. Diab
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • H. Tawbi
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • I. C. Glitza
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • W. J. Hwu
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • S. P. Patel
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • S. E. Woodman
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • R. N. Amaria
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • M. A. Davies
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • J. E. Gershenwald
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • P. Hwu
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • J. E. Lee
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • J. Zhang
    Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • L. M. Coussens
    Department of Cell, Developmental and Cell Biology, Oregon Health and Sciences University, Portland, OR 97239, USA.
  • Z. A. Cooper
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • P. A. Futreal
    Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • C. R. Daniel
    Department of Epidemiology, Human Genetics and Environmental Sciences, University of Texas School of Public Health, Houston, TX 77030, USA.
  • N. J. Ajami
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
  • J. F. Petrosino
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
  • M. T. Tetzlaff
    Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • P. Sharma
    Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • J. P. Allison
    Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • R. R. Jenq
    Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • J. A. Wargo
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

この論文をさがす

説明

<jats:title>Good bacteria help fight cancer</jats:title> <jats:p> Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy <jats:italic>et al.</jats:italic> show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium <jats:italic>Akkermansia muciniphila</jats:italic> . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson <jats:italic>et al.</jats:italic> and Gopalakrishnan <jats:italic>et al.</jats:italic> studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , this issue p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6371" page="91" related-article-type="in-this-issue" vol="359" xlink:href="10.1126/science.aan3706">91</jats:related-article> , p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6371" page="104" related-article-type="in-this-issue" vol="359" xlink:href="10.1126/science.aao3290">104</jats:related-article> , p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6371" page="97" related-article-type="in-this-issue" vol="359" xlink:href="10.1126/science.aan4236">97</jats:related-article> ; see also p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6371" page="32" related-article-type="in-this-issue" vol="359" xlink:href="10.1126/science.aar2946">32</jats:related-article> </jats:p>

収録刊行物

  • Science

    Science 359 (6371), 97-103, 2018-01-05

    American Association for the Advancement of Science (AAAS)

被引用文献 (75)*注記

もっと見る

参考文献 (76)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ